Actinic Keratosis Treatment Market Report by Type (Prescription, OTC), Drug Type (Fluorouracil, Imiquimod, Diclofenac, and Others), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2024-2032
세계 광선각화증 치료 시장 규모는 2023년 64억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 97억 달러에 달해 2024-2032년 사이 4.5%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다.
광선각화증이라고도 불리는 광선각화증은 햇빛에 노출된 부위에 발생하는 피부 질환을 말합니다. 손, 팔, 입술, 두피 및 기타 신체 부위에 거친 비늘 모양의 반점이 나타나며 편평상피암이라는 피부암으로 발전할 수 있습니다. 광 역학 치료에는 냉동 요법, 소파술, 레이저 요법 등이 있습니다. 현재 의료 인프라의 대폭적인 확대와 암 예방 전략에 대한 수요 증가는 전 세계 광선각화증 치료 수요에 긍정적인 영향을 미치고 있습니다.
광선각화증 치료 시장 동향
오존층 파괴와 과도한 햇빛 노출로 인한 광선각화증 유병률 증가는 시장 성장을 촉진하는 주요 요인 중 하나입니다. 또한, 암 발병률 증가와 최소침습(MI) 시술에 대한 수요 증가가 결합하여 시장 성장을 강화하고 있습니다. 또한, 주요 제조업체들이 크림 및 젤 형태의 광선각화증 치료를 출시하고 있으며, 이는 시장 성장을 촉진하고 있습니다. 이와는 별도로, 수많은 공공 및 민간 단체는 전 세계적으로 사용 가능한 광선각화증 치료법에 대한 인식을 높이기 위해 캠페인을 진행하는 데 주력하고 있습니다. 이와 더불어, 효능을 개선하고, 투여 편의성을 높이고, 비용을 절감하는 새로운 치료법을 개발하기 위한 연구 개발(R&D) 활동에 대한 막대한 투자도 시장 전망을 밝게 하고 있습니다. 또한, 흉터 발생 위험을 줄이는 국소 치료법의 채택도 시장을 주도하고 있습니다. 이 치료법은 피부의 눈에 보이거나 보이지 않는 병변을 광범위하게 치료하는 데에도 사용됩니다. 이 외에도 유리한 상환 정책은 시장 성장을 촉진할 것으로 예상됩니다.
본 보고서에서 다루는 주요 질문들
- 전 세계 광선각화증 치료 시장은 지금까지 어떻게 성장해 왔을까?
- COVID-19가 전 세계 광선각화증 치료 시장에 미치는 영향은?
- 주요 지역 시장이란?
- 유형별 시장 분석은?
- 약제 종류별 시장 현황은?
- 유통 채널별 시장 현황은?
- 산업 가치사슬의 다양한 단계는 무엇인가?
- 업계의 주요 촉진요인과 과제는 무엇인가?
- 세계 광선각화증 치료 시장 구조와 주요 진출 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 광선각화증 치료 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 내역 : 유형별
제7장 시장 내역 : 약물 유형별
제8장 시장 내역 : 유통 채널별
제9장 시장 내역 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
- 개요
- 구매자의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 참여업체의 위협
- 대체품의 위협
제13장 가격 분석
제14장 경쟁 상황
- 시장 구조
- 주요 기업
- 주요 기업 개요
- 3M Company
- Almirall SA
- Bausch Health Companies Inc.
- Biofrontera Inc.
- BioLineRx Ltd.
- Cipher Pharmaceuticals Inc
- Galderma SA
- Hill Dermaceuticals Inc.
- LEO Pharma A/S
- Sun Pharmaceutical Industries Ltd.
ksm
The global actinic keratosis treatment market size reached US$ 6.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.7 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032.
Actinic keratosis, also known as solar keratosis, refers to a skin condition that develops on the sun-exposed areas of the body. It causes rough, scaly patches to appear on the hands, arms, lips, scalp, and other body parts that can further develop into a skin cancer called squamous cell carcinoma. Some of the commonly used treatments to remove actinic keratosis include cryotherapy, curettage, laser therapy, and photodynamic therapy. At present, the considerably expanding healthcare infrastructure and increasing need for preventive strategies for cancer are positively influencing the demand for actinic keratosis treatment worldwide.
Actinic Keratosis Treatment Market Trends:
The increasing prevalence of actinic keratosis due to ozone layer depletion and excessive sun exposure represents one of the key factors fueling the growth of the market. Additionally, the rising incidences of cancer, coupled with the escalating demand for minimally invasive (MI) procedures, is strengthening the market growth. Furthermore, leading manufacturers are introducing medications for the treatment of actinic keratosis in the form of cream and gel, which is impelling the market growth. Apart from this, numerous public and private groups are focusing on conducting campaigns to generate awareness about available treatments for actinic keratosis across the globe. This, along with significant investments in the research and development (R&D) activities to develop novel therapies with improved efficacy, convenient dosage, and reduced costs, is creating a favorable market outlook. The market is also driven by the introduction of topical treatment that reduces the risk of scarring. This treatment is also used for treating a wide area of visible and invisible lesions on the skin. Besides this, favorable reimbursement policies are anticipated to fuel the market growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global actinic keratosis treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, drug type, and distribution channel.
Breakup by Type:
Prescription
OTC
Breakup by Drug Type:
Fluorouracil
Imiquimod
Diclofenac
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Almirall SA, Bausch Health Companies Inc., Biofrontera Inc., BioLineRx Ltd., Cipher Pharmaceuticals Inc, Galderma SA, Hill Dermaceuticals Inc., LEO Pharma A/S and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in This Report:
- How has the global actinic keratosis treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global actinic keratosis treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global actinic keratosis treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Actinic Keratosis Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Prescription
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 OTC
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Drug Type
- 7.1 Fluorouracil
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Imiquimod
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Diclofenac
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Distribution Channel
- 8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Drug Stores and Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Online Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 3M Company
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Almirall SA
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bausch Health Companies Inc.
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Biofrontera Inc.
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.5 BioLineRx Ltd.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 Cipher Pharmaceuticals Inc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Galderma SA
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 SWOT Analysis
- 14.3.8 Hill Dermaceuticals Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.9 LEO Pharma A/S
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.10 Sun Pharmaceutical Industries Ltd.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
